xRead - September 2022

Wise et al.

Page 398

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion

Cetirizine-pseudoephedrine was significantly better than placebo in improving nasal obstruction and airflow.

Loratadine-pseudoephedrine (either dose) was superior to placebo in reducing symptom scores.

Combination drug was significantly better than placebo in improving signs and TSS; both placebo and combination drug improved nasal symptoms.

Combination drug significantly reduced symptom scores and improved peak flow rates and FEV1 compared to placebo.

Combination was significantly more effecting in controlling all symptoms and providing more comfortable days than either medication alone.

Daily symptom scores Cetirizine-pseudoephedrine resulted in significantly reduced symptoms and more symptom-free days than either drug alone. Composite symptom scores: total, nasal and non-nasal

Combination drug was significantly superior to either drug alone or placebo in reducing symptom scores.

Nasal obstruction, nasal patency/airflow

Total nasal and non-nasal symptom scores

Nasal symptoms or signs, mean TSS

Nasal and chest symptoms, albuterol use, peak expiratory flow

5 daily symptoms: congestion, sneezing, rhinorrhea, nasal and ocular pruritus

1 Cetirizine-pseudoephedrine; 2 Placebo

1 Loratadine-pseudoephedrine once daily; 2 Loratadine-pseudoephedrine twice daily; 3 Placebo

1 Loratadine-pseudoephedrine; 2 Placebo

1 Loratadine-pseudoephedrine; 2 Placebo

1 Cetirizine-pseudoephedrine; 2 Cetirizine; 3 Pseudoephedrine

1 Cetirizine-pseudoephedrine; 2 Cetirizine; 3 Pseudoephedrine

1 Loratadine-pseudoephedrine; 2 Loratadine; 3 Pseudoephedrine; 4 Placebo

Study Year LOE

Horak et al. 1052 1998 1b RCT (n = 24):

Kaiser et al. 1450 1998 1b RCT (n = 469):

Serra et al. 1453 1998 1b RCT (n = 40):

Corren et al. 1454 1997 1b RCT (n = 193):

Grosclaude et al. 1459 1997 1b RCT (n = 687):

Bertrand et al. 1458 1996 1b RCT (n = 210):

Bronsky et al. 1455 1995 1b RCT (n = 874):

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.